Publications by authors named "R W Turkington"
The incidence of oesophageal adenocarcinoma (OAC) has risen six-fold in western countries over the last forty years but survival rates have only marginally improved. Hyperactivation of the PI3K-AKT-mTOR pathway is a common occurrence in OAC, driving cell survival, proliferation and resistance to chemotherapeutic agents. Inhibition of AKT has been explored as a treatment strategy with limited success and current inhibitors have failed to progress through clinical trials.
View Article and Find Full Text PDFBackground: The incidence of oesophageal adenocarcinoma (OAC) has been reported to be increasing in many countries. Alongside this trend, an increase in incidence of early-onset OAC, defined as OAC in adults aged under 50 years, has been observed. It is unclear whether survival outcomes for early-onset OAC patients differ from older age groups.
View Article and Find Full Text PDFArticle Synopsis
- - The DEBIOC trial explored the safety and efficacy of neoadjuvant treatment using oxaliplatin and capecitabine (Xelox) with or without AZD8931 in patients with oesophageal adenocarcinoma, showing moderate safety but limited effectiveness.
- - Researchers analyzed genetic data from 25 pre-treatment and 18 post-treatment biopsy samples to examine how these treatments influenced biological pathways related to cancer through advanced software tools.
- - Their findings identified three molecular subgroups linked to immune response, with treatment affecting immune signaling and tumor-infiltrating lymphocytes, while the addition of AZD8931 promoted a less favorable immunosuppressive environment and common cancer resistance mechanisms.
Background: An improved understanding of which gastroesophageal adenocarcinoma (GOA) patients respond to both chemotherapy and immune checkpoint inhibitors (ICI) is needed. We investigated the predictive role and underlying biology of a 44-gene DNA damage immune response (DDIR) signature in patients with advanced GOA.
Materials And Methods: Transcriptional profiling was carried out on pretreatment tissue from 252 GOA patients treated with platinum-based chemotherapy (three dose levels) within the randomized phase III GO2 trial.